Press release

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam”...

Banco Comercial Português, S.A. informs about Bank Millennium (Poland) results in H1 2024

English ...

EssilorLuxottica: Publication of the 2024 Interim Financial Report

Publication of the 2024 Interim Financial Report         Paris, France (July 26, 2024 – 6:30 pm) – The Board of Directors of...

CNOVA NV 2024 Second Quarter Activity & First Half Financial Performance

CNOVA N.V.First Half Financial performance & Second Quarter 2024 activityUpdate on Casino group situation Cnova pursues its path towards...

Endeavour Announces Holding(s) in Company

Endeavour Mining plc (“the Company”) announces that it received the following notification today, 26 July 2024 from Blackrock, Inc. of its...

China Baby Stores Market Research Report 2024 Featuring Alibaba, JD, Kidswant Children Products, Shanghai Aiyingshi, & Zhuhai LBaby New Retail Management

Dublin, July 26, 2024 (GLOBE NEWSWIRE) -- The "Baby Stores in China - Industry Market Research Report" report has been added to ResearchAndMarkets.com's...

Alliance Trust PLC – Net Asset Value

ALLIANCE TRUST PLC                 At the close of business on Thursday 25 July 2024: The Company’s NAV per ordinary share,...

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage...

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome,...

A one-time reminder to Liven AS green bond investors

A one-time reminder and information for Estonian resident individuals who have purchased or intend to purchase in the future Liven AS green...

Auction of Treasury Bills on 30 July 2024

The treasury bills for sale have the following stock exchange codes:         NameStock exchange codeMaturityDGTB 03/09/24 24 / III98-195833...

Webcast details for Orrön Energy’s Q2 presentation

Orrön Energy AB (“Orrön Energy”) will publish its financial report for the second quarter 2024 on Thursday, 8 August 2024 at 07:30 CEST,...

2024 H1 RESULTS Continued progress in operational performance Market prices decreasing Higher nuclear power output in France, expected at upper end of the range Lowest ever carbon intensity Success of commercial offers

2024 HALF-YEAR RESULTS Continued progress in operational performance Market prices decreasing Higher nuclear power output in France, expected...

Flow Traders 2Q 2024 Results

Flow Traders 2Q 2024 Results Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited 2Q 2024 results. Highlights...

LNG truck sales impacting Chinese road diesel demand

China’s sales of heavy-duty trucks powered by liquefied natural gas (LNG) rose from below 10% to reach as much as 30% of the market in the...

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent...

Vous recherchez un article plus ancien ?

Access the 24matins.uk archives